Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3115_Библиотеки_им_академика_М_И_Перельмана
.pdf
Rothman K. J., Greenland S. Types of Epidemiologic Studies / Rothman K. J.,
Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins,
1998. P. 67–78.
Vandenbroucke J. P., Pearce N. Case – control studies: basic concepts // International
Journal of Epidemiology. 2012. Vol. 41. № 5. P. 1480–1489.
Rubin D. B. Estimating causal effects of treatments in randomized and nonrandomized
studies // Journal of Educational Psychology. 1974. Vol. 66. № 5. P. 688–701.
Parascandola M. Two approaches to etiology: the debate over smoking and lung
cancer in the 1950s // Endeavour. 2004. June. Vol. 28. № 2. P. 81–86.
White C. Research on smoking and lung cancer: A landmark in the history of chronic
disease epidemiology // The Yale Journal of Biology and Medicine. 1990. Vol. 63. № 1. P.
29–46.
Mahmood S. S., Levy D., Vasan R. S., Wang T. J. The framingham heart study and the
epidemiology of cardiovascular diseases: A historical perspective // Lancet. 2014. March
15. Vol. 383. № 9921. P. 999–1008.
Song J. W., Chung K. C. Observational studies: Cohort and case-control studies //
Plastic and reconstructive surgery. 2010. December. Vol. 126. № 6. P. 2234–2242.
Ending the tobacco problem: A blueprint for the nation. Washington, DC: Institute of
Medicine, 2007.
Ridge C. A., McErlean A. M., Ginsberg M. S. Epidemiology of Lung Cancer //
Seminars in interventional radiology. 2013. June. Vol. 30. № 2. P. 93–98.
Talhout R., Schulz T., Florek E., Van Benthem J., Wester P., Opperhuizen A.
Hazardous compounds in tobacco smoke // International journal of environmental research
and public health. 2011. February. Vol. 8. № 2. P. 613–628.
Pfeifer G. P, Denissenko M. F., Olivier M., Tretyakova N., Hecht S. S., Hainaut P.
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated
cancers // Oncogene. 2002. October. Vol. 21. P. 7435–7451.
Hecht S. S. Tobacco smoke carcinogens and lung cancer // Journal of the National
Cancer Institute. 1999. July 21. Vol. 91. № 14. P. 1194–1210.
Hecht S. S. Carcinogenicity studies of inhaled cigarette smoke in laboratory animals:
old and new // Carcinogenesis. 2005. Vol. 26. № 9. P. 1488–1492.
Tobacco smoke and involuntary smoking / IARC monographs on the evaluation of
carcinogenic risks to humans. Vol. 83. International Agency for Research on Cancer, Lyon,
2004.
Glantz S. A., Bero L. A., Slade J., Barnes D. E., Hanauer P. (eds.). The Cigarette
Papers. University of California Press, 1998.
Fisher R. Cigarettes, cancer, and statistics // The Centennial Review of Arts &
Science. 1958. Vol. 2. P. 151–166.
Heath C. W. Differences between smokers and nonsmokers // Archives of Internal
Medicine. 1958. February. Vol. 101. № 2. P. 377–388.
Morris J. N., Crawford M. D. Coronary heart disease and physical activity of work:
Evidence of a national necropsy survey // British Medical Journal. 1958. December 20. Vol.
2. № 5111. P. 1485–1496.
Morris J. N., Clayton D. G., Everitt M. G., Semmence A. M., Burgess E. H. Exercise
in leisure time: coronary attack and death rates // British heart journal. 1990. Vol. 63. № 3.
https://t.me/medicina_free
P. 325–334.
Fedak K. M., Bernal,A., Capshaw Z. A., Gross S. Applying the Bradford Hill criteria
in the 21st century: how data integration has changed causal inference in molecular
epidemiology // Emerging themes in epidemiology. 2015. Vol. 12. № 1. P. 14.
Howick J., Glasziou P., Aronson J. K. The evolution of evidence hierarchies: what can
Bradford Hill’s ‘guidelines for causation’ contribute? // Journal of the Royal Society of
Medicine. 2009. Vol. 102. № 5. P. 186–194.
Di Cicco M. E., Ragazzo V., Jacinto T. Mortality in relation to smoking: the British
Doctors Study // Breathe (Sheffield, England). 2016. September. Vol. 12. № 3. P. 275–276.
Dearlove J. V., Bialous S. A., Glantz S. A. Tobacco industry manipulation of the
hospitality industry to maintain smoking in public places // Tobacco Control. 2002. Vol. 11.
№ 2. P. 94–104.
Smith C. N., Kraemer J. D., Johnson A. C., Mays D. Plain packaging of cigarettes: do
we have sufficient evidence? // Risk management and healthcare policy. 2015. Vol. 8. P. 21–
30.
Ong E. K., Glantz S. A. Constructing “sound science” and “good epidemiology”:
Tobacco, lawyers, and public relations firms // American journal of public health. 2001.
November. Vol. 91. № 11. P. 1749–1757.
Bero L. A. Tobacco industry manipulation of research // Public Health Reports. 2005.
March/April. Vol. 120. № 2. P. 200–208.
Velicer C., Helen G., Glantz S. A. Tobacco papers and tobacco industry ties in
regulatory toxicology and pharmacology // Journal of public health policy. 2018. February.
Vol. 39. № 1. P. 34–48.
Boffetta P., Couto E., Wichmann J., Ferrari P., Trichopoulos D. et al. Fruit and
vegetable intake and overall cancer risk in the European Prospective Investigation into
Cancer and Nutrition (EPIC) // Journal of the National Cancer Institute. 2010. April 21.
Vol. 102. № 8. P. 529–537.
Siontis G. C. M., Ioannidis J. P. A. Risk factors and interventions with statistically
significant tiny effects // International Journal of Epidemiology. 2011. October. Vol. 40. №
5. P. 1292–1307.
De Boer M., Van Leeuwen F. E., Hauptmann M., Overbeek L. et al Breast implants
and the risk of anaplastic large-cell lymphoma in the breast // JAMA Oncology. 2018. Vol.
4. № 3. P. 335–341.
Doren E. L., Miranda R. N., Selber J. C., Garvey P. B., Liu J., Medeiros L. J. et al. U.
S. epidemiology of breast implant-associated anaplastic large cell lymphoma // Plastic and
reconstructive surgery. 2017. May. Vol. 139. № 5. P. 1042–1050.
Bouvard V., Loomis D., Guyton K. Z., Grosse Y., Ghissassi F. et al. Carcinogenicity of
consumption of red and processed meat // Lancet Oncology. 2015. December. Vol. 16. P.
1599–1600.
Food, nutrition, physical activity, and the prevention of cancer: a global perspective.
World Cancer Research Fund / American Institute for Cancer Research. Washington DC:
AICR, 2007.
Chan D. S., Lau R., Aune D., Vieira R., Greenwood D. C., Kampman E., Norat T. Red
and processed meat and colorectal cancer incidence: meta-analysis of prospective studies //
PLoS One. 2011. Vol. 6. № 6, e20456.
https://t.me/medicina_free
Truswell A. S. Problems with red meat in the WCRF2 // American Journal of Clinical
Nutrition. 2009. Vol. 89. № 4. P. 1274–1275.
Wei E. K., Giovannucci E., Wu K., Rosner B., Fuchs C. S., Willett W. C., Colditz G.
A. Comparison of risk factors for colon and rectal cancer // International Journal of Cance.
2004. January 20. Vol. 108. № 3. P. 433–442.
Tai V., Grey A., Bolland M. J. Results of observational studies: analysis of findings
from the Nurses’ Health Study // PLoS One. 2014. Vol. 9. № 10, e110403.
https://t.me/medicina_free
Часть пятая
Overington J. P., Al-Lazikani B., Hopkins A. L. How many drug targets are there? //
Nature reviews. Drug discovery. 2006. December. Vol. 5. № 12. P. 993–996.
Kaplan R. M., Irvin V. L. Likelihood of null effects of large NHLBI clinical trials has
increased over time // Plos Оne. 2015. August 5. Vol. 10. № 8, e0132382.
Chalmers I., Glasziou P. Avoidable waste in the production and reporting of research
evidence // Lancet. 2009. Vol. 374. № 9683. P. 86–89.
Prinz F., Schlange T., Asadullah K. Believe it or not: how much can we rely on
published data on potential drug targets? // Nature Reviews Drug Discovery. 2011. Vol. 10.
№ 9. P. 712–713.
Begley C. G. Six red flags for suspect work // Nature. 2013. May 23. Vol. 497. №
7450. P. 433–434.
Begley C. G., Ellis L. M. Raise standards for preclinical cancer research // Nature.
2012. March 29. Vol. 483. P. 531–533.
Plourde G. Validation of surrogate endpoints for clinical trials // Journal of
Pharmacology & Clinical Research. 2018. Vol. 5. № 2, 555657.
Васильев А. Н., Ниязов Р. Р., Гавришина Е. В., Драницына М. А., Куличев Д. А.
Проблемы планирования и проведения доклинических исследований в Российской
Федерации // Ремедиум. 2017. № 9. C. 6–18.
Ganellin R., Roberts S. M., Jefferies R. (eds.) Introduction to biological and small
molecule drug research and development, theory and case studies. New York: Academic
Press, 2013.
Patnaik A., Kang S. P., Rasco D., Papadopoulos K. P., Elassaiss-Schaap J. et al. Phase
I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients With
Advanced Solid Tumors // Clinical Cancer Research. 2015. Vol. 21. № 19. P. 4286–4293.
Wong C. H., Siah K. W., Lo A. W. Estimation of clinical trial success rates and
related parameters // Biostatistics. 2018. January.
Lounnas V., Ritschel T., Kelder J., McGuire R., Bywater R. P., Foloppe N. Current
progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery
// Computational and structural biotechnology journal. 2013. Vol. 5. № 6, e201302011.
Thomas D. W., Burns J., Audette J., Carroll A., Dow-Hygelund C., Hay M. Clinical
development success rates 2006–2015. Biotechnology Innovation Organization. 2016. June.
P. 8.
Paul S. M., Mytelka D. S., Dunwiddie C. T., Persinger C. C., Munos B. H. et al. How
to improve R&D productivity: the pharmaceutical industry’s grand challenge // Nature
Reviews Drug Discovery. 2010. March. Vol. 9. № 3. P. 203–214.
Schuhmacher A., Gassmann O., Hinder M. Changing R&D models in research-based
pharmaceutical companies // Journal of translational medicine. 2016. Vol. 14. № 1. P. 105.
Arrowsmith J., Miller P. Trial watch: phase II and phase III attrition rates 2011–2012
// Nature reviews Drug discovery. 2013. August. Vol. 12. № 8. P. 569.
Chrisafis A. French drug trial leaves one brain dead and five critically ill // The
Guardian. 2016. January 15.
https://t.me/medicina_free
Symons X. Catastrophic result in clinical trial in France // BioEdge. 2016. January17.
Allen F. ‘Like a horror film’. What was the ‘Elephant Man’ drug testing trial, what is
TGN1412 and what happened to the men involved? // The Sun. 2017. February.
Attarwala H. TGN1412: From discovery to disaster // Journal of young pharmacists.
2010. July-September. Vol. 2. № 3. P. 332–336.
Tyrsin D., Chuvpilo S., Matskevich A., Nemenov D., Römer P. S., Tabares P., Hünig T.
From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development
for the treatment of rheumatoid arthritis // Clinical and experimental rheumatology. 2016.
July/August. Vol. 34. № 4 (Suppl 98). P. 45–48.
Hünig T. The rise and fall of the CD28 superagonis t TGN1412 and its return as
TAB08: a personal account // The FEBS Journal. 2016. Vol. 283. P. 3325–3334.
Frankos V. H. FDA perspectives on the use of teratology data for human risk
assessment // Fundamental and Applied Toxicology. 1985. August. Vol. 5. № 4. P. 615–625.
Schardein J. L. Chemically induced birth defects. New York: Marcel Dekker Inc, 1993.
Lumley C., Walker S. (eds.). Animal toxicity studies: their relevance for man. London:
Quay, 1990. P. 49–56.
Matthews R. A. J. Medical progress depends on animal models – doesn’t it? // Journal
of the Royal Society of Medicine. 2008. February. Vol. 101. № 2. P. 95–98.
Jones C. A., Watson D. J. G., Fone K. C. F. Animal models of schizophrenia // British
journal of pharmacology. 2011. October. Vol. 164. № 4. P. 1162–1194.
Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y.et al.
“Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better
understanding the causes to improve preclinical testing of immunotherapeutics // The
Journal of Immunology. 2007. Vol. 179. № 5. P. 3325–3331.
Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A. et al. Cytokine
storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 // The New
England Journal of Medicine. 2006. Vol. 355. № 10. P. 1018–1028.
Greek R., Shanks N., Rice M. J. The history and implications of testing thalidomide on
animals // The Journal of Philosophy, Science & Law. 2011. October. Vol. 11. № 3. P. 1–32.
Brent R. L. Drug testing in animals for teratogenic effects: Thalidomide in the
pregnant rat // The Journal of Pediatrics. 1964. May. Vol. 64. № 5. P. 762–770.
BaileyJ., Knight A., Balcombe J. The future of teratology research is in vitro //
Biogenic Amines. 2005. Vol. 19. № 2. P. 97–145.
Nelson-Rees W. A., Daniels D. W., Flandermeyer R. R. Cross-contamination of cells
in culture // Science. 1981. April 24. Vol. 212. № 4493. P. 446–452.
Nelson-Rees W. A., Flandermeyer R. R. Inter- and intraspecies contamination of
human breast tumor cell lines HBC and BrCa5 and other cell cultures // Science. 1977.
March 25. Vol. 195. № 4284. P. 1343–1344.
Lucey B. P., Nelson-Rees W. A., Hutchins G. M. Henrietta Lacks, HeLa cells, and cell
culture contamination // The Archives of Pathology & Laboratory Medicine. 2009. Vol.
133. № 9. P. 1463–1467.
Neimark J. Line of attack. Christopher Korch is adding up the costs of contaminated
cell lines // Science. 2015. February 27. Vol. 347. № 6225. P. 938–940.
Travis K. For phase I studies, ethical and practical concerns abound // Journal of the
National Cancer Institute. 2004. September 15. Vol. 96. № 18. P. 1354–1355.
https://t.me/medicina_free
Romm C. The life of a professional guinea pig // The Atlantic. 2015. September 23.
Lemmens T., Elliott C. Justice for the Professional Guinea Pig // The American
Journal of Bioethics. 2001. Vol. 1. № 2. P. 51–53.
Philippidis A. Unlucky 13: top clinical trial failures of 2017 // GEN. 2018. January 3.
Boolell M., Allen M. J., Ballard S. A., Gepi-Attee S., Muirhead G. J. et al. Sildenafil:
an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of
penile erectile dysfunction // International Journal of Impotence Research. 1996. June 1.
Vol. 8. № 2. P. 47–52.
Couzin-Frankel J. Hope in a mouse // Science. 2014. October 03. Vol. 346. № 6205. P.
28–29.
Benjamin D. J., Berger J. O., Johnson V. E. Redefine statistical significance // Nature
Human Behaviour. 2018. Vol. 2. № 1. P. 6–10.
Ioannidis J. P. A. Why most published research findings are false // PLoS Medicine.
2005. August 30. Vol. 2. № 8, e124.
Lakens D., Adolfi F. G., Albers C. J., Anvari F., Apps M. A. et al. Justify Your Alpha //
Nature Human Behaviour. 2018. March 1. Vol. 2. № 3. P. 168–171.
Рубанович А. В. Пересмотр критического уровня значимости (0.005 вместо
0.05): байесовский след // Радиационная биология. Радиоэкология. 2018. Т. 58. № 5. C.
453–463.
Head M. L., Holman L., Lanfear R., Kahn A. T., Jennions M. D. The extent and
consequences of p-hacking in science // PLoS Biology. 2015. Vol. 13. № 3, e1002106.
Jager L. R., Leek J. T. An estimate of the science-wise false discovery rate and
application to the top medical literature // Biostatistics. 2014. January 1. Vol. 15. № 1. P. 1–
12.
Геппе Н. А., Фарбер И. М., Озерская И. В., Малявина У. С., Малышев В. С.,
Бухаров Д. Г. Использование препарата Коризалия у детей с острым инфекционным
и персистирующим аллергическим ринитом // Доктор. Ру. 2017. № 4 (133). С. 54–60.
Petrov A., Perekhvatova N., Skulachev M., Stein L., Ousler G. SkQ1 ophthalmic
solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the
environment and during challenge in the controlled adverse environment model // Advances
in therapy. 2016. Vol. 33. № 1. P. 96–115.
Clinical trials often unregistered, unpublished // JAMA. 2017. September 11.
Chopra S. S. Industry funding of clinical trials: benefit or bias? // JAMA. 2003. Vol.
290. № 1. P. 113–114.
Als-Nielsen B., Chen W., Gluud C., Kjaergard L. L. Association of funding and
conclusions in randomized drug trials: a reflection of treatment effect or adverse events? //
JAMA. 2003. August 20. Vol. 290. № 7. P. 921–928.
Lundh A., Lexchin J., Mintzes B., Schroll J. B., Bero L. Industry sponsorship and
research outcome // Cochrane Systematic Review – Methodology. 2017. February 16.
Ioannidis J. P. A. Why most clinical research is not useful // PLoS Medicine. 2016.
June 21. Vol. 13. № 6, e1002049.
Macleod M. R., Michie S., Roberts I., Dirnagl U., Chalmers I., Ioannidis J. P A. et al.
Biomedical research: increasing value, reducing waste // Lancet. 2014. January 11. Vol.
383. № 9912. P. 101–104.
https://t.me/medicina_free
Ioannidis J. P. A., Greenland S., Hlatky M. A., Khoury M. J, Macleod M. R. et al.
Increasing value and reducing waste in research design, conduct, and analysis // Lancet.
2014. January 11. Vol. 383. № 9912. P. 166–175.
Ioannidis J. P. A. Perfect study, poor evidence: interpretation of biases preceding study
design // Seminars in hematology. 2008. July. Vol. 45. P. 160–166.
Jefferson T., Doshi P. Multisystem failure: the story of anti-influenza drugs // BMJ.
2014. April. Vol. 348, g2263.
Abramson J. D., Rosenberg H. G., Jewell N., Wright J. M. Should people at low risk of
cardiovascular disease take a statin? // BMJ. 2013. Vol. 347, f6123.
Ioannidis J. P. A. Contradicted and initially stronger effects in highly cited clinical
research // JAMA. 2005. July. Vol. 294. № 2. P. 218–228.
Djulbegovic B., Loughran T. P., Hornung C. A., Kloecker G., Efthimiadis E. N. et al.
The quality of medical evidence in hematology-oncology // The American journal of
medicine. 1999. February. Vol. 106. P. 198–205.
Isaakidis P., Swingler G. H., Pienaar E., Volmink J., Ioannidis J. P. Relation between
burden of disease and randomised evidence in sub-Saharan Africa: survey of research //
BMJ. 2002. March. Vol. 324. P. 702.
Swingler G. H., Pillay V., Pienaar E. D., Ioannidis J. P. International collaboration,
funding and association with burden of disease in randomized controlled trials in Africa //
Bulletin of the World Health Organization. 2005. July. Vol. 83. P. 511–517.
Goldberg N. H., Schneeweiss S., Kowal M. K., Gagne J. J. Availability of
Comparative Efficacy Data at the Time of Drug Approval in the United States // JAMA.
2011. May. Vol. 305. № 17. P. 1786–1789.
Van Luijn J. C., Van Loenen A. C., Gribnau F. W., Leufkens H. G. Choice of
comparator in active control trials of new drugs // Annals of Pharmacotherapy. 2008.
November. Vol. 42. № 11. P. 1605–1612.
Safer. D. J. Design and reporting modifications in industry-sponsored comparative
psychopharmacology trials // The Journal of nervous and mental disease. 2002. September.
Vol. 190. №. 9. P. 583–592.
Lapierre Y. D., Nair N. P., Chouinard G., Awad A. G., Saxena B., Jones B. et al. A
controlled dose-ranging study of remoxipride and haloperidol in schizophrenia – a
Canadian multicentre trial // Acta psychiatrica Scandinavica. 1990. April. Vol. 82. P. 72–
77.
Patris M., Agussol P., Alby J. M., Brion S., Burnat G., Castelnau D. et al. A double-
blind multicentre comparison of remoxipride, at two dose levels, and haloperidol // Acta
psychiatrica Scandinavica. 1990. April. Vol. 82. P. 78–82.
Ioannidis J. P. A. More than a billion people taking statins? Potential implications of
the new cardiovascular guidelines // JAMA. 2014. February 5. Vol. 311. № 5. Р. 463–464.
Pandor A., Ara R. M., Tumur I., Wilkinson A. J., Paisley S., Duenas A. et al.
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and
meta-analysis of randomized controlled trials // Journal of internal medicine. 2009. May.
Vol. 265. № 5. P. 568–580.
Doggrell S. A. The ezetimibe controversy – can this be resolved by comparing the
clinical trials with simvastatin and ezetimibe alone and together? // Expert opinion on
pharmacotherapy. 2012. July. Vol. 13. № 10. P. 1469–1480.
https://t.me/medicina_free
Brown B. G., Taylor A. J. Does ENHANCE diminish confidence in lowering LDL or in
ezetimibe? // The New England journal of Medicine. 2008. April 3. Vol. 358. P. 1504–1507.
Naci H., Ioannidis J. P. A. How good is “evidence” from clinical studies of drug
effects and why might such evidence fail in the prediction of the clinical utility of drugs? //
Annual review of pharmacology and toxicology. 2015. Vol. 55. P. 169–189.
Cohen D. Rosiglitazone: what went wrong? // BMJ. 2010. September. Vol. 341, c4848.
Harris G. Diabetes drug maker hid test data, files indicate // The New York Times.
2010. July 3.
Fleming T. R., Powers J. H. Biomarkers and surrogate endpoints in clinical trials //
Statistics in medicine. 2012. November 10. Vol. 31. № 25. P. 2973–2984.
Svensson S., Menkes D. B., Lexchin J. Surrogate outcomes in clinical trials: a
cautionary tale // JAMA. 2013. Vol. 173. № 8. P. 611–612.
Fleming T. R., DeMets D. L. Surrogate end points in clinical trials: are we being
misled? // Annals of Internal Medicine. 1996. October 1. Vol. 125. № 7. P. 605–613.
Gøtzsche P. C., Liberati A., Torri V., Rossetti L. Beware of Surrogate Outcome
Measures // International journal of technology assessment in health care. 1996. Vol. 12. №
2. P. 238–246.
Hewlett S., De Wit M., Richards P., Quest E., Hughes R., Heiberg T., Kirwan J.
Patients and professionals as research partners: Challenges, practicalities and benefits //
Arthritis & Rheumatism. 2006. August 15. Vol. 55. № 4. P. 676–680.
Hewlett S., Cockshott Z., Byron M., Kitchen K., Tipler S., Pope D., Hehir M. Patients’
perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored //
Arthritis & Rheumatism. 2005. October. Vol. 53. P. 697–702.
Hewlett S., Carr M., Ryan S., Kirwan J., Richards P., Carr A., Hughes R. Outcomes
generated by patients with rheumatoid arthritis: how important are they? //
Musculoskeletal care. 2005. Vol. 3. P. 131–142.
Rao J. K., Weinberger M., Kroenke K. Visit-specific expectations and patient-centered
outcomes: a literature review // Archives of family medicine. 2000. November. Vol. 9. №
10. P. 1148–1155.
Sherine E. G., Sharon-Lise T. N. Getting the methods right – The foundation of
patient-centered outcomes research // The New England journal of medicine. 2012. August.
Vol. 367. № 9. P. 787–790.
Podolanczuk A. J., Lederer D. J. Patient-centered outcomes in idiopathic pulmonary
fibrosis clinical trials // American Journal of Respiratory and Critical Care Medicine. 2017.
September 15. Vol. 196. № 6. P. 674–675.
Lassere M. N., Johnson K. R., Boers M., Tugwell P., Brooks P., Simon L., Strand V. et
al. Definitions and validation criteria for biomarkers and surrogate endpoints: development
and testing of a quantitative hierarchical levels of evidence schema // The Journal of
rheumatology. 2007. March. Vol. 34. № 3. P. 607–615.
Hunter D. J., Losina E., Guermazi A., Burstein D., Lassere M. N., Kraus V. A pathway
and approach to biomarker validation and qualification for osteoarthritis clinical trials //
Current drug targets. 2010. May. Vol. 11. № 5. P. 536–545.
Chan A.-W., Hróbjartsson A., Haahr M. T. et al. Empirical evidence for selective
reporting of outcomes in randomized trials: comparison of protocols to published articles //
JAMA. 2004. May 26. Vol. 291. № 20. P. 2457–2465.
https://t.me/medicina_free
Lee K. L., McNeer J. F., Starmer C. F., Harris P. J., Rosati R. A. Clinical judgment and
statistics. Lessons from a simulated randomized trial in coronary artery disease //
Circulation. 1980. March. Vol. 61. № 3. P. 508–515.
Rothwell P. M. Treating individuals 2. Subgroup analysis in randomised controlled
trials: importance, indications, and interpretation // Lancet. 2005. January. Vol. 365. P.
176–186.
Stallones R. A. The use and abuse of subgroup analysis in epidemiological research //
Preventive medicine. 1987. March. Vol. 16. № 2. P. 183–194.
Oxman A. D., Guyatt G. H. A Consumer’s guide to subgroup analyses // Annals of
internal medicine. 1992. January. Vol. 116. № 1. P. 78–84.
Sterne J. A. C., Smith G. D. Sifting the evidence – what’s wrong with significance
tests? // Physical Therapy. 2001. August 1. Vol. 81. № 8. P. 1464–1469.
Guyatt G., Jaeschke R., Heddle N., Cook D., Shannon H., Walter S. Basic statistics for
clinicians: 2. Interpreting study results: confidence intervals // Canadian Medical
Association journal. 1995. January. Vol. 152. № 2. P. 169–173.
Kääriäinen I., Sipponen P., Siurala M. What fraction of hospital ulcer patients is
eligible for prospective drug trials? // Scandinavian journal of gastroenterology. 1991. Vol.
26. № 186. P. 73–76.
Charlson M. E., Horwitz R. I. Applying results of randomised trials to clinical
practice: impact of losses before randomisation // British medical journal. 1984. November
10. Vol. 289. P. 1281–1284.
Simpson S. H., Eurich D. T., Majumdar S. R., Padwal R. S., Tsuyuki R. T. et al. A
meta-analysis of the association between adherence to drug therapy and mortality // BMJ.
2006. July 1. Vol. 333. № 7557.
Mitchell J. “But will it help my patients with myocardial infarction?” The implications
of recent trials for everyday country folk // British Medical Journal. 1982. October 23. Vol.
285. P. 1140–1148.
Shepherd J. Statins for primary prevention: strategic options to save lives and money //
Journal of the Royal Society of Medicine. 2004. February. Vol. 97. № 2. P. 66–71.
Asymptomatic Carotid Atherosclerosis Study Group. Carotid endarterectomy for
patients with asymptomatic internal carotid artery stenosis // JAMA. 1995. Vol. 273. P.
1421–1428.
Moore W. S., Young B., Baker W. H. et al. Surgical results: a justification of the
surgeon selection process for the ACAS trial // Journal of Vascular Surgery. 1996. Vol. 23.
P. 323–328.
Bond R., Rerkasem K., Rothwell P. M. High morbidity due to endarterectomy for
asymptomatic carotid stenosis // Cerebrovascular diseases. 2003. Vol. 16.
Vesper I. Europe’s academics fail to report results for 90% of clinical trials // Nature.
2018. September 13.
Plint A. C., Moher D., Morrison A., Schulz K., Altman D. G., Hill C., Gaboury I. Does
the CONSORT checklist improve the quality of reports of randomised controlled trials? A
systematic review // The Medical journal of Australia. 2006. September. Vol. 185. № 5. P.
263–267.
Rothstein H. R., Sutton A. J., Borenstein M. (eds). Publication Bias in Meta-analysis.
West Sussex, England: Wiley, 2005.
https://t.me/medicina_free
Tong C. H., Tong L.-I., Tong J. E. The Vioxx recall case and comments //
Competitiveness Review. Vol. 19. № 2. P. 114–118.
Psaty B. M., Kronmal R. A. Reporting mortality findings in trials of rofecoxib for
Alzheimer disease or cognitive impairment: a case study based on documents from
rofecoxib litigation // JAMA. 2008. Vol. 299. № 15. P. 1813–1817.
Topol E. J. Failing the public health – rofecoxib, Merck, and the FDA // The New
England journal of Medicine. 2004. October 21. Vol. 351. P. 1707–1709.
Berenson A. Evidence in Vioxx suits shows intervention by Merck officials // The New
York Times. 2005. April 24.
Curfman G. D., Morrissey S., Drazen J. M. Expression of concern: Bombardier et al.,
“Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with
rheumatoid arthritis” // New England Journal of Medicine. 2000. Vol. 343. P. 1520–1528.
Egilman D. S., Presler A. H. Report of specific cardiovascular outcomes of the
ADVANTAGE trial // Annals of internal medicine. 2006. May 16. Vol. 144. № 10. P. 781.
Nelson L. D. False-positives, p-hacking, statistical power, and evidential value.
University of California, Berkeley, Haas School of Business, Summer Institute. 2014.
Dickersin K. How important is publication bias? A synthesis of available data // AIDS
education and prevention. 1997. Vol. 9. P. 15–21.
Turner E. H., Matthews A. M., Linardatos E., Tell R. A., Rosenthal R. Selective
publication of antidepressant. Trials and its influence on apparent efficacy // New England
Journal of Medicine. 2008. Vol. 358. № 3. P. 252–260.
Rising K., Bacchetti P., Bero L. Reporting bias in drug trials submitted to the Food
and Drug Administration: review of publication and presentation // Plos Medicine. 2008.
November 25. Vol. 5. № 11, e217.
Scharf O., Colevas A. D. Adverse event reporting in publications compared with
sponsor database for cancer clinical trials // Journal of clinical oncology. 2006. August 20.
Vol. 24. № 24. P. 3933–3938.
MacLean C. H., Morton S. C., Ofman J. J., Roth E. A., Shekelle P. G. How useful are
unpublished data from the Food and Drug Administration in meta-analysis? // Journal of
clinical epidemiology. 2003. Vol. 56. P. 44–51.
Chan A.-W., Krleža-Jerić K., Schmid I., Altman D. G. Outcome reporting bias in
randomized trials funded by the Canadian Institutes of Health Research // CMAJ. 2004.
September 28. Vol. 171. № 7. P. 735–740.
Dwan K., Altman D. G., Arnaiz J. A., Bloom J., Chan A.-W., Cronin E. et al.
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome
Reporting Bias // PLOS One. 2008. August 28. Vol. 3. № 8, e3081.
Lee K. P., Boyd E. A., Holroyd-Leduc J. M., Bacchetti P., Bero L. A. Predictors of
publication: characteristics of submitted manuscripts associated with acceptance at major
biomedical journals // The Medical journal of Australia. 2006. June 19. Vol. 184. № 12. P.
621–626.
Ioannidis J., Lau J. Evolution of treatment effects over time: Empirical insight from
recursive cumulative metaanalyses // PNAS. 2001. January 30. Vol. 98. № 3. P. 831–836.
Ross J. S., Mulvey G. K., Hines E. M., Nissen S. E., Krumholz H. M. Trial publication
after registration in clinical trials. Gov: a cross-sectional analysis // Plos Medicine. 2009.
September 8. Vol. 6. № 9, e1000144.
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана